Evotec SE (XSWX:EVT) NonCurrent Deferred Liabilities: CHF138.8 Mil (As of Mar. 2026)


XSWX:EVT Evotec SE XSWX:EVT
64 GF Score
Price CHF4.63
GF Value CHF6.85
! 5 Warning Signs
View Full Analysis

What is Evotec SE NonCurrent Deferred Liabilities?

Evotec SE XSWX:EVT 64 NonCurrent Deferred Liabilities is CHF138.8 Mil as of Mar. 2026. GuruFocus rates XSWX:EVT with a GF Score™ of 64/100 and a GF Value™ of CHF6.85. The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Evotec SE's non-current deferred liabilities for the quarter that ended in Mar. 2026 was CHF138.8 Mil.

Evotec SE NonCurrent Deferred Liabilities Related Terms

Evotec SE NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Evotec SE's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE NonCurrent Deferred Liabilities Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.29 221.71 163.55 188.36 157.15

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 226.45 191.28 179.50 157.15 138.77
XSWX:EVT
64GF Score
Evotec SE XSWX:EVT
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of CHF138.8 Mil mean?
Evotec SE (XSWX:EVT) has a NonCurrent Deferred Liabilities of CHF138.8 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Evotec SE and its competitors.
Is Evotec SE's NonCurrent Deferred Liabilities too high?
Evotec SE's current NonCurrent Deferred Liabilities is CHF138.8 Mil. Overall, Evotec SE has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's NonCurrent Deferred Liabilities compare to ZTS and UTHR?
Evotec SE's NonCurrent Deferred Liabilities of CHF138.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Evotec SE and its competitors. Evotec SE's current NonCurrent Deferred Liabilities is CHF138.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (XSWX:EVT) has a current NonCurrent Deferred Liabilities of CHF138.8 Mil. The stock's GF Value™ is CHF6.85, compared to a current price of CHF4.63 — trading 32.4% below its estimated fair value. The current NonCurrent Deferred Liabilities is CHF138.8 Mil. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current NonCurrent Deferred Liabilities is CHF138.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (XSWX:EVT) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of CHF4.63 is trading 32.4% below its estimated GF Value™ of CHF6.85.

Key valuation signals for XSWX:EVT:

  • NonCurrent Deferred Liabilities: CHF138.8 Mil
  • GF Value™: CHF6.85 vs. price of CHF4.63 (32.4% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score

Get the complete analysis for XSWX:EVT

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF4.63
Price
CHF6.85
GF Value